Chronic obstructive pulmonary disease (COPD) patients newly prescribed non-benzodiazepine receptor agonists (NBZRAs) such as zolpidem (Ambien, Intermezzo, and other brands), a class of hypnotic drugs prescribed for insomnia, did not have an increased risk of exacerbations requiring hospitalizations or of death than those prescribed other types of hypnotics, according to research published at the ATS…
Sleep Consortium and RARE-X, the Global Genes research program and patient-owned data collection platform, are collaborating to launch the Sleep Data Collection Initiative to accelerate the development of treatments for central disorders of hypersomnolence and related conditions. Phase 1 of the Sleep Data Collection Initiative has four main objectives: bring together a multi-disciplinary workgroup to…
Glidewell has announced a new addition to its family of sleep solutions: the flexTAP mandibular advancement device (MAD). The oral appliance treats snoring and mild to moderate obstructive sleep apnea. It’s an extension of the TAP line of sleep appliances offered by Glidewell. “We’re pleased to introduce the flexTAP appliance,” says Peter Tran, preventive care…
Audio Transcript Hello, APJ listeners. Thanks for spending so much time with Pastor John and me over the years. We’re honored to be along on this ride of what God has done — and continues to do — through the podcast. It’s bigger than us. It’s just me today, with an update for you about…
Recently, our family was staying with a family we love when they suffered a miscarriage. The wife had just finished her first trimester. The baby would have been number six for them, their second son, a boy they all loved deeply without meeting him. The family wept for hours. Now, I could say more about…
By Daniel N. Alvarez Núñez and Ivonne Alejandra Méndez Ávila The current pace of life has led many people to sacrifice sleep to pursue academic achievements, work goals, or social commitments. While we often worry more about the physical repercussions of lack of sleep, the psychological consequences are impactful too. Sleep is divided into two…
LifeQ, a provider of biometrics and health information derived from wearables, unveiled a new 24-hour sleep solution for clinicians and patients designed to help uncover sleep disorders and improve sleep quality, health, and wellness. The sleep solution harnesses the power of wearables, identifying and classifying all sleep within a 24-hour period, providing insights beyond the…
Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, presented positive results from the MARIPOSA phase 2b trial, an efficacy, safety, and dose-finding study of AD109 over a one-month duration, at the ATS 2023 International Conference. On the trial’s primary endpoint of…
Nox Health Group is set to acquire Somryst, the sole US Food and Drug Administration (FDA)-authorized prescription digital therapeutic for chronic insomnia treatment, from Pear Therapeutics after being selected as the successful bidder at auction. Pear filed for Chapter 11 bankruptcy last month, and an auction to divest the company’s assets was held last week,…